オプションチェーンは、NovoCureの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、NovoCureの市場センチメントを評価します。.

NovoCure (NASDAQ:NVCR) 株価情報, オプションチェーン

NovoCure

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

NovoCure Ltd

Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) reported quarterly earnings of $1.41 per share which beat the analyst consensus estimate of $1.30 by 8.46 percent. This is a 0.7 percent decrease over earnings of $1.42 per share from the same period last year. The company reported quarterly sales of $1.18 billion which met the analyst consensus estimate. This is a 3.32 percent increase over sales of $1.15 billion the same period last year.

Earnings

Earnings Beats

News

Zoom Video Comms Q4 2025 Adj EPS $1.41 Beats $1.30 Estimate, Sales $1.18B Inline

WIIM

BBIO

BridgeBio Pharma shares are trading lower after the company announced a $500 million proposed offering of convertible senior notes to refinance its senior secured debt.

Netstreit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTST#NYSE">NTST</a>) reported quarterly earnings of $0.32 per share which met the analyst consensus estimate. This is a 3.23 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $44.10 million which beat the analyst consensus estimate of $41.04 million by 7.45 percent. This is a 19.64 percent increase over sales of $36.86 million the same period last year.

NTST

Netstreit Q4 AFFO $0.32, Inline, Sales $44.10M Beat $41.04M Estimate

Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.40 by 25 percent. This is a 38.89 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $93.500 million which beat the analyst consensus estimate of $91.025 million by 2.72 percent. This is a 5.40 percent decrease over sales of $98.840 million the same period last year.

FARO

Faro Technologies Q4 2024 Adj. EPS $0.50 Beats $0.40 Estimate, Sales $93.500M Beat $91.025M Estimate

Offerings

BridgeBio Announces  $500M Proposed Offering Of Convertible Senior Notes To Refinance Senior Secured Debt

DMC Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) sees Q1 sales of $146.000 million-$154.000 million vs $145.55 million analyst estimate.

Guidance

BOOM

DMC Glb Sees Q1 Sales $146.000M-$154.000M vs $145.55M Est

2025 Guidance
BWXT announced its expectations for fiscal year 2025 financial results, providing the following guidance:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(In millions, except per share amounts)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Year Ended</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Year Ending</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">December 31, 2024</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">December 31, 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Results</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Guidance(2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2,704</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~$3,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA(1)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$499</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$550 - $570</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP(1) Earnings Per Share</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$3.33</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$3.40 - $3.55</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow(1)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$255</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$265 - $285</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(2) BWXT has not included a reconciliation of provided non-GAAP guidance to comparable GAAP measures due to the difficulty of estimating any mark-to-market adjustments for pension and post-retirement benefits, which are determined at the end of the year.</td>
</tr>
</tbody>
</table>
</figure>
Additional information can be found in the 2024 fourth quarter earnings call presentation on the BWXT investor relations website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.bwxt.com%2F&amp;esheet=54213125&amp;newsitemid=20250224459539&amp;lan=en-US&amp;anchor=investors.bwxt.com&amp;index=2&amp;md5=b7aedb6d3a846a0f185f64cb000e7a97">investors.bwxt.com</a>. The Company does not provide GAAP guidance because it is unable to reliably forecast most of the items that are excluded from GAAP to calculate non-GAAP results. These items could cause GAAP results to differ materially from non-GAAP results.

BWXT

BWX Technologies Sees FY25 EPS $3.40-$3.55 Vs $3.43 Est.; Revenue ~$3B Vs $2.898B Est.

DMC Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.29) by 131.03 percent. This is a 65.38 percent decrease over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $152.37 million which beat the analyst consensus estimate of $140.50 million by 8.45 percent. This is a 12.45 percent decrease over sales of $174.04 million the same period last year.

DMC Glb Q4 Adj $0.09 Beats $(0.29) Estimate, Sales $152.37M Beat $140.50M Estimate

Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) reported quarterly earnings of $1.07 per share which missed the analyst consensus estimate of $1.35 by 20.74 percent. This is a 18.94 percent decrease over earnings of $1.32 per share from the same period last year. The company reported quarterly sales of $297.100 million which beat the analyst consensus estimate of $291.526 million by 1.91 percent. This is a 7.51 percent increase over sales of $276.351 million the same period last year.

Earnings Misses

ADUS

Addus HomeCare Q4 2024 Adj. EPS $1.07 Misses $1.35 Estimate, Sales $297.100M Beat $291.526M Estimate

CWEN

Clearway Energy Reaffirms  2025 Full Year CAFD Guidance Range Of $400M - $440M

CLNE

Clean Energy Fuels shares are trading lower after the company reported mixed Q4 financial results.

VCYT

Veracyte Sees FY25 Testing Revenue $470M-$480M.

BWX Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.81 by 13.58 percent. This is a 8.91 percent decrease over earnings of $1.01 per share from the same period last year. The company reported quarterly sales of $746.27 million which beat the analyst consensus estimate of $719.98 million by 3.65 percent. This is a 2.86 percent increase over sales of $725.51 million the same period last year.

BWX Technologies Q4 Adj $0.92 Beats $0.81 Estimate, Sales $746.27M Beat $719.98M Estimate

Clean Energy Fuels FY25 Net Loss ~$(160)M-$(155)M

Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) reported quarterly earnings of $0.11 per share which met the analyst consensus estimate. This is a 1000 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $481.14 million which beat the analyst consensus estimate of $470.31 million by 2.30 percent. This is a 95.09 percent increase over sales of $246.62 million the same period last year.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Q4 2024 GAAP EPS $0.11, Inline, Sales $481.14M Beat $470.31M Estimate

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) affirms FY2025 Adj EPS guidance from $0.07-$0.11 to $0.07-$0.11 vs $0.06 analyst estimate. Affirms FY2025 sales outlook from $840.00 million-$860.00 million to $840.00 million-$860.00 million vs $866.15 million estimate.

MYGN

Myriad Genetics Affirms FY2025 Adj EPS Guidance of $0.07-$0.11 vs $0.06 Est; Affirms FY2025 Sales Guidance of $840.00M-$860.00M vs $866.15M Est

GFL Environmental Q4 2024 Adj. EPS C$(0.52), Sales C$1.986B

Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.11 by 45.45 percent. This is a 20 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $118.600 million which beat the analyst consensus estimate of $116.765 million by 1.57 percent. This is a 20.78 percent increase over sales of $98.199 million the same period last year.

Veracyte Q4 2024 Adj. EPS $0.06 Misses $0.11 Estimate, Sales $118.600M Beat $116.765M Estimate

Clean Energy Fuels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNE#NASDAQ">CLNE</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.02) by 200 percent. This is a 100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $109.326 which missed the analyst consensus estimate of $102.618 million by 100.00 percent. This is a 100.00 percent decrease over sales of $106.857 million the same period last year.

Clean Energy Fuels Q4 2024 Adj. EPS $0.02 Beats $(0.02) Estimate, Sales $109.326 Miss $102.618M Estimate

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) reported quarterly earnings of $0.03 per share which met the analyst consensus estimate. This is a 25 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $210.60 million which missed the analyst consensus estimate of $211.62 million by 0.48 percent. This is a 7.12 percent increase over sales of $196.60 million the same period last year.

Myriad Genetics Q4 Adj $0.03, Inline, Sales $210.60M Miss $211.62M Estimate

Press Releases

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

Novocure Reports Third Quarter 2024 Financial Results

Novocure Appoints Christoph Brackmann as Chief Financial Officer

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Novocure to Participate in Upcoming Investor Conferences

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Comments

NovoCure

NovoCure (NVCR) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル